VR Adviser, LLC Q4 2020 Filing
Filed February 12, 2021
Portfolio Value
$680.1B
Holdings
25
Report Date
Q4 2020
Filing Type
13F-HR
All Holdings (25 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | —CONSTELLATION PHARMACEUTICAL | 4,016,873 | $115.7B | 17.01% | |
| 2 | OLMAOLEMA PHARMACEUTICALS INC | 1,536,193 | $73.9B | 10.86% | |
| 3 | TREURTRILLIUM THERAPEUTICS INC | 4,040,000 | $59.4B | 8.74% | |
| 4 | —KINNATE BIOPHARMA INC | 1,473,014 | $58.6B | 8.62% | |
| 5 | —ATHIRA PHARMA INC | 1,691,623 | $57.9B | 8.52% | |
| 6 | ALTALTIMMUNE INC | 4,500,000 | $50.8B | 7.46% | |
| 7 | KROSKEROS THERAPEUTICS INC | 672,306 | $47.4B | 6.97% | |
| 8 | MRNS*MARINUS PHARMACEUTICALS INC | 2,588,941 | $31.6B | 4.64% | |
| 9 | SNDXSYNDAX PHARMACEUTICALS INC | 1,115,255 | $24.8B | 3.65% | |
| 10 | RLMDRELMADA THERAPEUTICS INC | 668,440 | $21.4B | 3.15% | |
| 11 | KURAKURA ONCOLOGY INC | 575,000 | $18.8B | 2.76% | |
| 12 | VTGNUSDVISTAGEN THERAPEUTICS INC | 9,360,000 | $18.2B | 2.67% | |
| 13 | TCE2CELLDEX THERAPEUTICS INC | 800,000 | $14.0B | 2.06% | |
| 14 | SURFUSDSURFACE ONCOLOGY INC | 1,442,895 | $13.3B | 1.96% | |
| 15 | ACRSACLARIS THERAPEUTICS INC | 1,954,932 | $12.6B | 1.86% | |
| 16 | COGTCOGENT BIOSCIENCES INC | 1,088,817 | $12.2B | 1.80% | |
| 17 | ALGSALIGOS THERAPEUTICS INC | 404,906 | $11.2B | 1.65% | |
| 18 | GRTXGALERA THERAPEUTICS INC | 917,860 | $9.4B | 1.38% | |
| 19 | SPRYSILVERBACK THERAPEUTICS INC | 150,000 | $7.0B | 1.02% | |
| 20 | —BCTG ACQUISITION CORP | 500,000 | $5.7B | 0.84% | |
| 21 | —METACRINE INC | 693,673 | $5.5B | 0.80% | |
| 22 | —FIVE PRIME THERAPEUTICS INC | 245,122 | $4.2B | 0.61% | |
| 23 | BCABBIOATLA INC | 100,000 | $3.4B | 0.50% | |
| 24 | TSHATAYSHA GENE THERAPIES INC | 107,982 | $2.9B | 0.42% | |
| 25 | VRDNVIRIDIAN THERAPEUTICS INC | 19,495 | $321.0M | 0.05% |